APA (7th ed.) Citation

Jones, J. A., Robak, T., Brown, J. R., Awan, F. T., Badoux, X., Coutre, S., . . . Owen, C. (2017). Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: An open-label, randomised phase 3 trial. The Lancet. Haematology, 4(3), e114. https://doi.org/10.1016/S2352-3026(17)30019-4

Chicago Style (17th ed.) Citation

Jones, Jeffrey A., et al. "Efficacy and Safety of Idelalisib in Combination with Ofatumumab for Previously Treated Chronic Lymphocytic Leukaemia: An Open-label, Randomised Phase 3 Trial." The Lancet. Haematology 4, no. 3 (2017): e114. https://doi.org/10.1016/S2352-3026(17)30019-4.

MLA (9th ed.) Citation

Jones, Jeffrey A., et al. "Efficacy and Safety of Idelalisib in Combination with Ofatumumab for Previously Treated Chronic Lymphocytic Leukaemia: An Open-label, Randomised Phase 3 Trial." The Lancet. Haematology, vol. 4, no. 3, 2017, p. e114, https://doi.org/10.1016/S2352-3026(17)30019-4.